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Background: The unique immunomodulatory capacity of helminth parasites has
been investigated as a novel strategy in the prevention of allograft rejection after
transplantation. This review was conducted to fully evaluate the specific effects of
helminth therapy on allograft survival reported in published studies of animal models of
allogeneic transplantation.
Method: Following PRISMA protocol guidelines, a literature search was conducted
using PubMed, MEDLINE via OvidSP, along with additional manual searches of
selected reference lists. Publications describing helminth intervention within allograft
transplantation models were screened for relevance to eligibility criteria. Primary and
secondary outcomes were extracted using standardized data collection tables. The
SYRCLE risk of bias assessment tool was used for quality assessment. Due to
heterogeneity of study designs, meta-analysis could not be performed; rather outcomes
are presented as a narrative synthesis with concept mapping. This review was registered
in PROSPERO with ID: CRD42018097175.
Results: The literature search generated 1,443 publications, which after screening for
relevance to the eligibility criteria yielded 15 publications for qualitative analysis. All 15
publications reported improvement to allograft survival as a result of helminth therapy.
This prolonged allograft survival was not significantly different when helminth-derived
products were used compared to live infection. However, the extent of positive impact
on allograft survival was noted to be dependent on study design factors, such as
the chronicity of the live helminth infection, allograft type and the species/genus of
helminth selected.
Conclusion: Both live and product-based helminth therapy have potential applications
as novel immune regulators or adjuncts for the prevention of allograft rejection.
However, there were differences in efficacy between different worms and preparations
of worm-derived products. Therefore, further studies are required to determine the most
appropriate worm for a specific allograft, to elucidate the optimal dose and route of
administration, and to better understand the modulation of immune responses that can
mediate tolerance.
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BACKGROUND
Parasitic worms (helminths) are a highly divergent group of
macro-pathogens consisting of two major phyla: the Nematoda
(or roundworms) and the Platyhelminthes (also known as
flatworms), with the latter consisting of both trematodes (flukes)
and cestodes (tapeworms) (1). Reflecting this diversity, the course
of infection in mammalian hosts varies greatly for different
helminths. For example, infection with Trichinella spiralis occurs
through ingestion of meat that is contaminated with the larval
stage of the parasite. In the case of schistosomiasis, infection
occurs after the parasite cercaria is released from its intermediate
snail host and burrows through the skin of its mammalian
host. Larvae migrate through the lung and heart before they
mature in the liver. Although infection with Nippostrongylus
brasiliensis also occurs through subcutaneous infection, unlike
the schistosomes that ultimately inhabit the mesenteric blood
vessels, N. brasiliensis larvae exit the circulation into the lungs
and are coughed up and swallowed, eventually residing in the
intestine of its chosen mammalian hosts. Despite such diversity
in the morphology and life cycles of individual helminths,
this group of parasites induces a stereotypical Th2 immune
response, characterized by the presence of cytokines IL-4, IL-5,
IL-13, and IL-10, antibody isotypes IgG1, IgG4, and IgE, and
expanded populations of eosinophils, mast cells, basophils and
M2 macrophages (2).
It has been proposed that this specific profile of immune
response has evolved as a mechanism to regulate the extensive
tissue damage caused by these macro-pathogens as they migrate
through the host, resulting in a dynamic co-evolution between
the host and the parasite (2, 3). Indeed, the Th2 immune
response during parasite infection appears to be initiated by
pro-inflammatory cytokines released from damaged or disrupted
epithelial cells, with the resultant activation of M2 macrophages
and Th2 cells in particular contributing to the host mechanisms
of rapid tissue repair through the deposition of extracellular
matrix proteins (2, 4).
In contrast to micro-pathogens, such as bacteria, protozoa,
and viruses, most helminths do not replicate in their mammalian
hosts. Instead, the infective stages must establish infection and
then grow to sexual maturity, producing eggs or live offspring
for transmission to the next host. Therefore, maintaining host
fitness is in the best interest of the parasite. This is supported
by the observation that in addition to host signals of damage,
a number of parasite-secreted compounds also modulate host
immune responses to ensure a positive outcome for both host and
parasite (4, 5).
Frequently, helminth parasites establish chronic infections
and if untreated can persist for decades in the tissue of their
hosts. During these long-term infections, it has been noted that
the dynamics of the T cell response changes over time. To
Abbreviations: ELISA, enzyme-linked immunosorbent assay; FACS,
Fluorescence-activated cell sorting; IP, intra-peritoneal; LNFP-III, Lacto-N-
fucopentaose III; NTP, Neutral thiol protease; PCR, polymerase chain reaction;
SC, subcutaneous; TsE, Trichinella spiralis extract.
prevent excessive tissue repair, which may result in fibrosis-
related pathology, the Th2 response often declines during
chronic infection and is replaced with the development of
regulatory pathways, including the differentiation of regulatory
T cells (Tregs). This transition, actively initiated by both host
and parasite signals, ensures the fine-tuning of the parasite-
driven immune response to restrain pathological outcomes
(5, 6).
This potent modulation of host immunity by helminths
has additional unintended consequences, resulting in the
regulation of a variety of inflammatory conditions caused
by a dysregulated immune response, such as rheumatoid
arthritis, multiple sclerosis, ulcerative colitis, type 1 and 2
diabetes, and sepsis (7–10). In both natural and experimental
helminth infections, there is a clear inverse relationship
between the presence of parasites and the progression of
inflammatory disease (11–13). These observations have led
to the proposition of helminth therapy. However, due to
the challenges of manufacturing a consistent batch of live
parasites from mammalian hosts that is acceptable to current
regulatory standards, combined with concern regarding the
pathology of parasite infection, there has not been broad clinical
support for the use of live infections as a therapeutic strategy.
As such, the focus of this field of research has shifted to the
characterization of the molecules that are excreted and secreted
by helminths to support the pharmacological development of
worm-derived immunomodulators as therapeutics or to exploit
their mechanism of action to develop small molecule drugs
(14–16).
In light of this immunomodulatory capability, many
have suggested extending the use of helminth therapy to
the prevention of allograft rejection. Successful allograft
transplantation is continually plagued by the challenge of
both acute and chronic cell mediated allograft rejection
(17). This process is mediated through both indirect
and direct forms of antigen recognition and is typically
regulated through the release of pro-inflammatory Th1
cytokines (17, 18). Current immunosuppressive regimens
aim to dampen cell-mediated rejection by targeting various
immune cell interactions. Although successful in suppressing
allograft rejection, these immunosuppressive agents carry
significant toxicities, and their use can lead to increased
rates of infection and malignancies and can also be toxic
to the transplanted organ (19, 20). Considering this,
the potential application of helminths as a natural, novel
immune regulatory therapy for allograft rejection represents a
therapeutic advantage.
To date, there has been no single comprehensive study
on the use of helminth therapy as an adjunct to traditional
immunosuppressive therapy. In particular, the analysis of the
impacts of study design, the choice of parasite, and importantly,
the difference between live and product-based helminth therapy
on the survival of allografts has not been determined. Therefore,
this systematic review aims to apply these considerations to the
qualitative analysis of published studies to better characterize the
effects of live and product-based helminth therapy on the survival
of allogeneic transplants.
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METHODS
This systematic review was conducted according to the
provided Preferred Reporting Items for Systematic Reviews and
Meta-Analysis guidelines (PRISMA) (21) and registered with
PROSPERO (registration number: CRD42018097175).
Information Sources and Literature Search
Strategy
Publications were gathered from database searches of PubMed
and Medline via OvidSP. Additional publications were
compiled from reference lists of literature reviews and included
studies until January 2020. The following search terms were
utilized for both databases: (helminth∗ OR nematode OR
trematode OR cestode OR worm∗ OR “parasitic worm∗” OR
schistosome∗ OR trichuris OR nippostrongylus OR fluke OR
tapeworm OR hookworm) AND (transplant∗ OR allograft
OR “allograft survival” OR “skin graft”). Publications were
screened for duplicates and for relevance to outlined criteria. A
secondary reviewer provided resolution to any discrepancies in
publication relevance.
Eligibility Criteria and Study Selection
This review focused on the impact of helminthic therapy
on allograft survival. To be eligible, studies were required to
investigate any model of allogeneic organ transplantation and
consider the following criteria:
Interventions
Any form of helminthic therapy, including live and helminth-
derived products, in any form or species/genus, dose, and route
of administration or duration, in comparison to placebo/control
group were considered for review. Helminth derived products
could involve any form including native secretions of a parasite,
soluble worm extracts from homogenous worms or eggs and
purified recombinant single proteins derived from helminths.
Placebo/control groups were considered as any treatment not
containing helminthic intervention, e.g., saline.
Populations
All animal populations were considered for review. There were
no exclusions relating to age, species, or weight of animals.
Study Design
All forms of study design were included for review, irrespective
of sample size.
Outcomes
For inclusion, the administration of helminths in any form must
have impacted allograft survival. Any studies in which helminth
infection occurred but was not implemented as a treatment
were excluded.
Exclusion
Non-English publications and review publications and papers
not available in full paper form were excluded for review.
Additionally, in vitro and in silico studies were not considered.
Data Items and Data Collection Process
All eligible publications were reviewed, and relevant data items
were extracted using a standardized data collection table. Data
items provided in the collection table included publication date,
helminth genus/species, allograft model, live or product-based
therapy, parasite burden, administration route and time, as well
as worm life stage and sample size. Data items were organized
into groups according to helminth genus type before identifying
live or product-based therapeutic design. Within product-based
therapeutic designs, studies were further grouped according to
product type, such as soluble worm extracts, native secretions
of the worm, and purified recombinant proteins. Outcomes and
results were assessed in comparison to control, with allograft
survival recorded as rejection (days post-transplantation).
Bias and Quality Assessment
Bias was assessed by two reviewers using an adapted form of the
SYRCLE risk of bias assessment tool, a version of the Cochrane
RoB tool (22). Items 1, 3, 5, and 6 were removed, as they were
unlikely to impact on the outcomes of the publications. Each
reviewer assessed bias according to the questions within each
item, indicating risk of bias by answering yes, no or unclear
to the guided questions. Discrepancies in answers between each
reviewer were resolved by discussion with a third reviewer. The
percentage of bias present for each publication was determined
by reporting the percentage yes, no and unclear answers in a bar
graph. Bias was also reported as a quality assessment score and
averaged for each item of the assessment tool. Publications that
failed to report at least 50% of the items were considered of poor
quality and hence excluded from this review.
Summary Measures and Synthesis of
Results
Due to heterogeneity of the publications, meta-analysis was
not applicable for this systematic review. Studies are instead
presented in narrative synthesis, detailing the effect of helminth
therapy on allograft survival. The primary outcomes of graft
survival (days post-transplantation) was reported in addition
to supplementary data presented in each study, including
immunohistochemistry, flow cytometry and serum cytokine
detection. Differences in graft survival for each allograft
presented, were compared by considering the helminth genus
and species, allograft type, and parasite burden utilized. In
addition, the effect of live and product-based intervention type
was considered for its impact on graft survival. These were then
presented as concept maps to visualize the impact of such study
design characteristics on the primary outcome.
RESULTS
Study Selection
As shown in Figure 1, the initial database and manual reference
list search yielded 1,443 publications. Removal of duplicates left
989 publications, of which 861 publications were excluded based
on irrelevance. The remaining 131 publications were assessed for
eligibility based upon inclusion criteria, resulting in a further 116
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FIGURE 1 | PRISMA flowchart of study selection.
being excluded. A total of 15 relevant publications were included
for review.
Study Characteristics
The characteristics of the included studies are summarized
in Supplementary Table 1. Studies ranged in publication dates
from 1969 to 2016. Sample sizes ranged from 5 to 100, with a total
of 339 animals infected with live helminth or helminth-derived
products across all allograft transplant studies.
The effects of helminth therapy were investigated within
multiple allograft models including skin (n = 9) (23–31), heart
(n = 3) (32–34), kidney (n = 1) (35), and liver (n = 1) (36).
One study investigated both skin and heart allograft models
(37). Helminth intervention varied according to species/genus,
parasite burden, live or product based and administration route.
Five different helminths were utilized as treatment, including
Echinococcus multilocularis (n = 2) (32, 36), Nippostrongylus
brasiliensis (n= 2) (34, 35), Schistosomamansoni (n= 2) (24, 33),
Paragonimus westermani (n = 1) (29), Trichinella spiralis (n =
6) (25–28, 30, 37), and a combination of Trichinella spiralis and
Trichinella pseudospiralis (n = 2) (23, 31). Helminth therapy
was divided into live (n = 9) (24, 26–28, 30, 32, 34, 36, 37)
and product-based (n = 2) (29, 33) treatment, with four studies
investigating the difference between live and product-based
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intervention (23, 25, 31, 35). Within these publications, product
based therapeutics were defined as soluble worm extracts (n= 5)
(23, 25, 29, 35), native secretions from the worm (n = 1) (23),
or purified recombinant proteins (n = 1) (33). Administration
of these therapies was given as intraperitoneal (n = 4) (24,
29, 32, 36), oral intubation/probe (n = 5) (23, 26–28, 37), and
subcutaneous injection (n= 3) (33–35). One publication did not
clearly define administration (30), whilst two other publications
used a combination of oral/intraperitoneal injection (25) or
intraperitoneal/subcutaneous injection (31). Each intervention
was also altered in accordance with parasite burden.
The primary outcome of all publications was allograft survival.
This was described as time until graft rejection (days post-
transplant) for control vs. treatment for the vast majority of
studies. One publication did not report the time until graft
rejection (33). Graft rejection was clearly defined (with specific
descriptions for distinct transplant types) as bleeding and
shrinking of graft (n= 2) (23, 24), necrosis (n= 7) (25–28, 30, 31,
36), 80% or more induration and no hair growth (n= 2) (29, 37),
loss of graft function (n= 1) (34) increases to morbidity signs (n
= 1) (35), or cessation of cardiac beating (n= 3) (32, 33, 37).
Whilst the majority of publications primarily reported
allograft survival as the only outcome, six publications also
reported secondary measures to confirm improved allograft
survival. These were reported as a combination of histopathology
and immunohistochemistry (n = 4) (32, 35–37), flow cytometry
(n = 6) (32–37), direct cytotoxic T lymphocyte activity (n =
1) (34), serum cytokine detection by Luminex or ELISA (n =
3) (34, 36, 37), and PCR (n = 1) (36). In addition, three of
the publications noted that the immune modulation induced by
helminths involved T regulatory cells (32, 33, 37).
Bias and Quality Assessment
The results of the SYRCLE bias assessment of the 15 publications
included in this systematic review are reported in Table 1 and
Figure 2. The overall quality of all publications was high, with
no studies excluded on this basis. Across all 15 publications,
an average of four out of the six chosen items were adequately
reported. Three papers reported all six items to give the highest
quality scores, and four papers only reported three of the six
items, giving the lowest quality scores.
Most of the publications were unclear on their reporting
of randomization and blinding. Reports of random housing
were unclear in 53% of publications and blinding of outcome
assessors was unclear in 40%. These two features were deemed
in this review to be of minimal importance for the assessment
of allograft rejection. Importantly, 93% of included publications
reported similar baseline characteristics, a necessary component
for comparing animals in transplantation studies. Additionally,
87% of publications were free from other sources of bias.
Individual Study Results and Synthesis of
Results
All 15 publications reported significant improvements to
allograft survival with the administration of both live and
product-based helminth therapy (Figure 3). Alterations to study
design features including, helminth genus/species, parasite











































































































































































Ai Erken et al. (32)
Alkarmi et al. (23)
Araujo et al. (24)
Barriga et al. (25)
Chernyakhovskaya et al. (26)
Chimyshkyan et al. (27)
Dutta et al. (33)
Deng et al. (37)
Faubert et al. (28)
Hamajima et al. (29)
Ledingham et al. (35)
Li et al. (36)
Liwski et al. (34)
Svet-Moldavsky et al. (30)
Szkudlinski et al. (31)
Low risk Unclear risk High risk.
burden, and allograft type, showed an impact on the extent
of allograft survival. The results of these publications are
summarized in Table 2.
Allograft Survival
Allograft survival was significantly improved in helminth-
treated groups when compared to control-treated groups within
12 of the 15 publications, illustrated by reports of marked
decreases to necrotic lesions at the allograft site. Only one
study noted no improvement to allograft survival with the
administration of a soluble worm extract, despite seeing
improvements to allograft survival with the administration
of infective larvae or secretions from the same worm in
the same transplant model (23). Helminth administration of
both live and product-based interventions improved allograft
survival by an average of 13.6 days across all studies. The
minimum improvement to graft survival of 2.1 days was
observed with the administration of an extract isolated from
100mg of T. spiralis larvae within a skin graft model
(31). The maximum improvement to graft survival was 86
days in a skin graft model involving the administration
of 30 µg/kg of neutral thiol protease isolated from P.
westermani (29).
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FIGURE 2 | Quality assessment score, averaged per item.
FIGURE 3 | Allograft survival across reviewed publications. Entries show study types differing by treatment type (live vs. helminth extract/secretion), and
administration timeframe relative to transplantation. Almost all publications reported significant improvements to allograft survival with the administration of helminth
therapy regardless of live or product-based therapeutic forms. Only one publication reported no significant difference to allograft survival with the administration of
soluble worm extracts, but had increased survival with all other treatment forms (23). Additionally, two papers did not find significant improvement despite
demonstrating considerable trends in allograft survival (26, 30). Three papers were excluded from analysis noting that a clear survival time in days was not provided.
Key: ♦ indicates same helminth treatment applied to different transplanted organs. # indicates differing timing of helminth administration. Sec, secretion; TS, T. spiralis;
TP, T. pseudospiralis. *p < 0.05, **p < 0.01, ***p < 0.001.
Frontiers in Immunology | www.frontiersin.org 6 August 2020 | Volume 11 | Article 1604
Kiss et al. Helminth Therapy Preventing Transplant Rejection
Improved allograft survival was supported in six studies
by supplementary secondary analysis in the form of
immunohistochemistry, flow cytometry and/or serum cytokine
detection. Using these different analytical approaches revealed
a predominant switch in the phenotype of immune response.
The prolonged allograft survival mediated by live infection was
consistently associated with a significant decrease in the levels of
pro-inflammatory cytokines (primarily IFNγ and IL-17) and a
parallel increase in Th2/Treg cytokines (IL-4 and IL-10) (34–37).
Supporting these observations, a number of studies showed
increased numbers of Tregs (Foxp3+, CD25+) within the graft
tissue in response to both helminth infection and administration
of helminth-derived products (32, 33, 37). In addition, there
were larger quantities of eosinophils in graft tissue of animals
receiving helminth therapy (32, 33).
Impacts of Study Design
Helminth Genus and Species
Within two studies of skin allograft transplantation,
administration of live T. spiralis and T. pseudospiralis larvae
produced similar improvements to allograft survival in
comparison to control (23, 31), suggesting that alteration of
the parasite species does not impact the positive outcome.
In contrast, changing the helminth genus resulted in altered
impacts to allograft survival. Across two studies with similar
study design (administering 70–90 larvae within a skin allograft
model), a change from the genus Schistosoma to Trichinella
vastly improved allograft survival from 13.93 to 26.2 days
(24, 27). This effect was also seen in two different studies
where they compared the administration of Echinococcus
or Trichinella within heart allograft models, with allograft
survival extending from 16.17 to 23.4 days, respectively
(32, 37).
Chronicity and Worm Burden of Helminth Infection
The duration of the parasite infections appeared to influence
the outcome of allograft survival. Administration of 75–85 T.
spiralis larvae 23 days prior to the transplantation of a skin
graft elicited greater graft survival (26.2 days) than larvae given
7 days before (17.2 days) (30). As helminths do not replicate
in their hosts, but rather produce eggs for transmission, this
difference in outcome cannot be attributed to an increase in
parasite numbers over time. However, increasing the worm
burden does have a positive impact on graft survival. Increasing
the infective dose of T. spiralis or T. pseudospiralis to 300
larvae resulted in the same improvement in allograft survival
(24 and 26 days) (23) as the long-term infection, despite
being delivered 3 days post-transplant. The importance of
worm burden is further supported in rat models of solid
organ transplant, where the administration of 800 larvae of N.
brasiliensis 4 days prior to a heart transplant resulted in allograft
survival to 20–26 days, compared to 9–12 days for the controls
(34). Increasing the infective burden to 3,500 larvae further
extended the survival of a solid organ (kidney) allograft to 32.7
days (35).
Therapeutic Differences Between Live and
Product-Based Helminth Therapies
Of the live infection therapies, administration of N. brasiliensis
showed the most significant prolongation of graft survival (34).
However, overall, across all studies the largest increase to allograft
survival was seen with the administration of a recombinant
protein derived from P. westermani, which showed an extension
of allograft survival 86 days beyond that seen in the control
animals (control: 18± 0.5, treatment: 104± 33, p < 0.05) (29).
A direct comparison between live infection and the
administration of helminth-derived products was specifically
investigated within four separate studies (23, 25, 31, 35). Each
publication maintained identical helminth genus or species,
only differing in the type of product and administration route.
Within a skin graft model, the administration of 45 live T.
spiralis larvae by the natural route of infection (oral inoculation)
induced no difference in graft survival when compared to that
induced by a single IP injection of 0.2mg of a soluble protein
extract of the same parasite (25). Both prolonged allograft
survival to between 18 and 23 days in comparison to the 12–18
days seen with control (25). Similar results were also achieved
within another skin allograft model, in which either T. spiralis
or T. pseudospiralis was administered as either a live infection
(80–100 larvae orally) or a soluble worm extract (prepared from
100mg larvae) (31). Differences in graft survival prolongation
were minimal for both species: T. spiralis (live: 24.9 ± 0.5
days, extract: 23.9 ± 0.7 days); T. pseudospiralis (live: 24.8 ±
0.5, extract: 24.8 ± 0.6 days, control: 21.8 ± 0.5). In contrast,
another skin graft study which tested the same parasite species
showed that live infection of either species (300 larvae delivered
orally) resulted in extended allograft survival to 24 days whilst
the IP administration of soluble worm extract (50 µg) did not
significantly extend graft survival past that of the control group
(day 8) (23). Thus, in the application of Trichinella species,
the administration of low quantities (50 µg) of either native
secretions or a soluble extract of the worm were less effective
or ineffective, respectively, in preventing the rejection of skin
grafts compared to studies where either higher doses (designed
to imitate the presence of live worms) or live infection was used.
This observation was supported by a study in a kidney allograft
model (35), where the administration of 3,500 N. brasiliensis
larvae markedly improved allograft survival to 32.7 ± 11.3 days,
whilst the administration of a soluble worm extract collected
from 200 larvae only increased graft survival to 21.5 ± 4.6 days
(control: 9.7± 1.2 days, p < 0.001).
Allograft Type
Differences in the type of allograft model used also impacted
on the extent of allograft survival. The smallest improvement to
allograft survival was seen with skin allografts. This effect was
well-modeled within one investigation of the effects of 300 T.
spiralis larvae on both heart and skin allografts (37). Whilst the
allograft survival of both transplant types was prolonged with
helminth administration when compared to control, the effect in
the heart model was greater, with graft survival extended to 23.4
days in comparison to 10.6 days for control (p < 0.01). Within
the skin model, allograft survival was limited to 13.67 days in




































TABLE 2 | Impacts of study design on allograft survival.















Ai Erkien et al. (32) Echinococcus
multilocularis
Rat heart Live 20% larval suspension
IP injection
Larvae
Not defined 7.92 ± 1.93 16.17 ± 3.19 <0.05
Li et al. (36) Echinococcus
multilocularis
Rat liver Live 20% larval suspension
IP injection
Larvae
Not defined 9.9 ± 2.3 15.5 ± 3.9 <0.05
HELMINTH GENUS: SCHISTOSOME
Araujo et al. (24) Schistosoma mansoni Mouse skin Live 80 cercariae
IP injection
Cercariae
30 days prior 10 13.93 <0.001









1 day prior and 4 days
post-transplant









1 day prior and 4 days
post-transplant
Not defined Not defined 0.008
HELMINTH GENUS: PARAGONIMUS
Hamajima et al. (29) Paragonimus
westermani




Neutral thiol protease (NTP)
from larvae
4 days prior 18 ± 0.5 104 ± 33 <0.05
HELMINTH GENUS: NIPPOSTRONGYLUS
Ledingham et al. (35) Nippostrongylus
brasiliensis
Rat kidney Live 3,500 larvae
SC injection
Larval
4 days prior 9.7 ± 1.2 32.7 ± 11.3 <0.001
Nippostrongylus
brasiliensis





4 days prior 9.7 ± 1.2 21.5 ± 4.6 <0.001
Liwski et al. (34) Nippostrongylus
brasiliensis
Mouse heart Live 800 larvae
SC injection
Larval
4 days prior Between days 9 and 12 Between days 20 and 26 <0.03
HELMINTH GENUS: TRICHENELLA
Alkarmi et al. (23) Trichinella spiralis Mouse skin Live 300 larvae
Oral inoculation
Larval




















































































TABLE 2 | Continued
















Mouse skin Live 300 larvae
Oral inoculation
Larval
3 days post-transplant 7 26 <0.01





Various days post-transplant8 8 Not stated
Trichinella
pseudospiralis





Various days post-transplant8 8 Not stated





Various days post-transplant8 13 <0.01
Trichinella
pseudospiralis





Various days post-transplant8 14 <0.01
Barriga et al. (25) Trichinella spiralis Mouse skin Live 45 larvae
Oral inoculation
Larval
29 days prior Between 12 and 18 days Between 18 and 23 days Not stated





29 days prior Between 12 and 18 days Between 18 and 23 days Not stated
Chernyakhovskaya
et al. (26)
Trichinella spiralis Mouse skin Live 70–90 larvae
Oral Inoculation Larval
27 days prior 9.5 15 Not stated
Chimyshkyan et al. (27) Trichinella spiralis Mouse skin Live 70–90 larvae
Oral Inoculation
Larval
Not defined 12.5 26.2 <0.001
Deng et al. (37) Trichinella spiralis Mouse heart Live 300 larvae
Oral Inoculation Larval
28 days prior 10.60 ± 0.75 23.40 ± 1.99 <0.01
Trichinella spiralis Mouse skin Live 300 larvae
Oral Inoculation Larval
28 days prior 8.17 ± 0.40 13.67 ± 0.56 <0.01




Up to 3 days prior 9 ± 0.6 15 ± 0.6 <0.001
Trichinella spiralis Mouse skin Live 500 larvae
Oral inoculation Larval
30 days prior 9 ± 0.6 17 ± 0.7 <0.001
Svet-Moldavsky et al.
(30)
Trichinella spiralis Mouse skin Live 75–85 larvae
Unclear
Larval
23 days prior 12.3 26.2 Not stated
Trichinella spiralis Mouse skin Live 75–85 larvae
Unclear
Larval



















































































































































































































































































































































































































































































































































































comparison to control (p < 0.01). The graft survival duration
for other solid organ (heart and liver) transplants were similarly
impacted by helminth infection. Two studies investigating the
effect of E. multilocularis live therapy on both liver and heart
allografts (32, 36) were matched according to administration and
dosing. Both liver (15.5 days, p< 0.05) and heart (16.17 days, p<
0.05) allografts survived to a similar extent in each study. These
comparisons stand as evidence for the differences in allograft
survival being influenced by the type of tissue being transplanted.
DISCUSSION
Summary of Evidence
This systematic review has determined that in all 15 publications
allograft survival was significantly improved in helminth-treated
groups, with all studies reporting marked decrease in graft
necrosis. The positive impacts of helminth therapy on allograft
survival were clearly seen across multiple animal models of
allogeneic transplantation. The finding that both live infection
and the administration of helminth-derived products were both
effective at preventing allograft rejection, is consistent with a
previous literature review of this topic (38) and suggests that
parasite secreted molecules can be as efficacious as live infection.
This similarity in outcomes could be attributed (with the support
of data presented in six of the fifteen publications) to a common
mechanism of immune modulation. Both parasite infection and
the administration of a recombinant version of a parasite-derived
protein resulted in a decreased pro-inflammatory immune
response concomitant with a rise in Th2/Treg immune response;
a profile of immunity known to support the prolonged survival
of a transplanted graft (18).
The effectiveness of the helminth therapy evaluated in the
15 publications appeared to be dependent on the type of tissue
that was transplanted. This was most strikingly evident in a
comparison between the survival of a skin and heart allograft
after infection with T. spiralis, with the heart surviving 10 days
longer than the skin graft (37). It has long been noted that
skin grafts are more readily rejected than heart transplants (39).
Skin grafts are considered to be more potent stimulators of the
immune system as they contain large numbers of Langerhans
cells, a population of cells with excellent antigen presentation
ability (40). In addition, it has been demonstrated that the
slow nature of developing vasculature in skin grafts (days for
skin grafts vs. hours for heart grafts) results in prolonged
ischemic injury which, in turn, stimulates inflammatory signals
that increase T cell priming and migration to the site of
transplantation (41). It has also been reported that simply the
difference in size of the transplanted tissue influences the rate of
rejection, as larger number of effector T cells are needed for the
destruction of a donor heart in comparison to a skin graft (42).
While the immune response in the parasite infected recipients of
heart and skin grafts was not compared, it could be hypothesized
that the modulation of immune responses in this instance by the
parasite was simply not sufficient to counteract the acute and
potent inflammation driven by the skin graft.
Two elements of a helminth infection dictate the profile
and potency of the host’s immune response; time and worm
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burden. For some parasites, the development of the characteristic
predominance of Th2/Treg immune response takes time as it is
often dependent on the maturation of the parasite, the deposition
of eggs, or simply the time it takes to migrate to the anatomical
location in which they ultimately reside (43–45). In addition,
it has been reported that individuals harboring greater worm
numbers display a stronger regulatory response (46). In the skin
and heart transplant studies mice were infected with T. spiralis 28
days prior to transplantation (23, 37). For this particular parasite,
a Th2 immune response is immediately induced after infection
in mice, developing into a mixed Th17/Th2 response in the
proceeding weeks post-infection, followed by a predominating
Treg population (47, 48). This would suggest that the presence
of a regulatory T cell population at the time of transplantation,
which although effective against the heart transplant, did not
impact the immune response to a great enough extent for the skin
graft. Such a notion could be supported by the observation that
the infection of mice with the same dose (300 larvae) of T. spiralis
3 days after a skin transplantation resulted in the survival of the
graft for 24 days, compared to 13 days when the parasite was
administered 28 days before transplantation (23, 37). Although
not examined, perhaps the nature of the immediate Th2 immune
response induced by the infection with the parasite around the
time of transplantation was more appropriate to regulate the
inflammation induced by the skin graft.
The importance of inducing the correct immune response to
facilitate transplant survival is also illustrated when comparing
the outcomes of infection with different genera of parasites. On
the surface it appears that infection with live Trichinella species
are far more effective in preventing skin transplant rejection
compared to S. mansoni (24, 27). However, in contrast to the
delivery of Trichinella larvae, S. mansoni was not administered
via its natural route of infection (skin), which likely impacted on
the ability of the parasite to fully modulate the immune response
as expected.
Understanding the biology of the parasite to better exploit
its immune modulating power becomes even more critical in
the selection and analysis of the efficacy of helminth-derived
products. This is most evidently demonstrated in a skin graft
study that compared the impact of live infection with either T.
spiralis or T. pseudospiralis to the IP administration of soluble
extracts of worms (50 µg) and to an IP injection of the native
secretions of the parasite (50 µg) (23). It is assumed that the
immunemodulators produced by helminth parasites are typically
found within their secreted products, as these are the compounds
most likely to directly interact with the host immune cells (15). In
contrast, experimentally prepared extracts contain the complete
soluble protein content from homogenized worms, some of
which are originally produced to function intracellularly within
the parasite and not in the external environment of the host
tissue. Reflecting this adaptation of biological function, the IP
administration of the native secretions extended the allograft
survival to 14 days in this model (23). Although this is less
effective than oral infection (24–26 days), it was a significant
(p < 0.01) improvement compared to the same dose of soluble
extracts prepared by either homogenizing the worms (8 days)
or the control group (7 days). To properly compare the native
secretions of the parasite to the live infection, a dose which
more accurately represents the quantity of proteins secreted by
an equivalent number of larvae should be administered to the
transplant recipient.
An alternative explanation for the reduced efficacy of the
native secretions compared to live infection is that the continued
presence of the parasite may be necessary to elicit the regulatory
immune response in the host (7, 49). However, this seems less
likely when the results from the two studies that utilized isolated
helminth-derived products are evaluated. Only two injections
(50 µg) of a recombinantly produced version of the S. mansoni
pentasaccharide LNFP-III were required to extend median graft
survival of heart transplant compared to controls (33). This
molecule is found on the surface of the eggs of S. mansoni,
the production of which coincides with the development of a
potent Th2/Treg immune response in this parasite infection (43).
The positive impact on the heart transplant was mediated by
the differentiation of macrophages toward an M2 phenotype,
which subsequently promoted the accumulation of Tregs in the
draining lymph nodes of the donor organs. Adoptive transfer
of these LNFP-III activated macrophages was sufficient to also
significantly prolong allograft survival (33). Perhaps even more
effective was the native neutral-thiol protease harvested from the
secretions of P. westermani, as only a single IP injection was
required to provide the greatest protection to the graft across all
of the studies examined, extending the survival of a skin graft
to 86 days beyond the control animals (29). Furthermore, the
dose of protein delivered (30 µg/kg) was far lower than any
of the other experiments that described the effect of soluble
extracts or secreted products (50–200 µg per mouse). This
protein is naturally secreted by the parasite and acts as a
cysteine protease with a broad substrate specificity supporting
the cleavage of a broad range of host proteins (50) suggesting
an ability to interfere with the host immune signaling proteins
and possibly contribute to the potent effect observed in this
transplant model.
Limitations
The review was restricted by the lack of immunological evidence
presented in each paper. Of the 15 publications evaluated, nine
provided the primary outcome of allograft survival with no
additional supporting evidence of immune profiling. This placed
limitations on the conclusions that could be drawn, meaning
that similarities and differences between therapies on allograft
survival could only be assumed based on our current knowledge
of transplant and parasite immunology. Additionally, due to the
heterogeneous nature of all publications meta-analysis could not
be performed, and thus a subjective qualitative synthesis was
used for analysis. To reduce the subjective nature of this analysis,
input from multiple reviewers was gathered when performing
the narrative synthesis. Despite this, lack of statistical evidence
does preclude the application of this review to influence the
development of helminth-based therapies for enhanced allograft
survival. In future, further publications with similar study designs
may allow for meta-analysis to validate the conclusions found in
this review.
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FIGURE 4 | A summary of the immune profile, parasite and graft type which reported optimal improvements to allograft survival.
CONCLUSIONS
Despite the limitations, this review provides comparative
evaluation of the effects of helminth therapy on allograft survival
across multiple models of allogeneic transplantation. While
variations in efficacy were most notably linked to the timing and
dose of helminth therapy, and to the choice of allograft model, it
was clear that all publications reported improvements to allograft
survival with the administration of both live and product-based
helminth therapy. It is evident that a better understanding of
the immune changes induced by the parasites and their products
will be essential to developing the most effective therapeutic
strategy for specific allografts. Furthermore, to elucidate which
parasite-derived molecules are likely to be most effective, a
more appropriate analysis of these compounds is required,
with consideration for their known or predicted biological
function in the host. Nonetheless, the evidence presented here
supports the proposition that helminth therapy represents a
viable treatment form of immunosuppressive therapy. By careful
selection of the helminths or helminth products that are best
suited to particular allograft types and consideration of the
required dose/chronicity to induce themost appropriate immune
response, an optimal protocol can be achieved to provide
the most significant immunomodulation to promote successful
allograft survival (Figure 4).
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